Article Text

Download PDFPDF
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists


Background: Blockage of tumour necrosis factor α (TNFα) is highly effective in rheumatic diseases, especially in rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Furthermore, TNFα antagonists have also been shown to significantly reduce psoriatic skin lesions.

Case reports: A series of nine patients with RA who were treated with different types of TNFα antagonists and who unexpectedly developed either a new onset or an exacerbation of psoriatic skin lesions are reported

  • LEF, leflunomide
  • MTX, methotrexate
  • RA, rheumatoid arthritis
  • TNFα, tumour necrosis factor α
  • psoriasis
  • tumour necrosis factor antagonists
  • side effects
  • rheumatoid arthritis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.